Targeted Replacement

APOE2 Targeted Replacement Mouse Model

C57BL/6NTac Background

  • Model #
  • Genotype
  • Nomenclature
  • 1547-F
    B6.129P2-Apoetm1(APOE*2)Mae N9
  • 1547-M
    B6.129P2-Apoetm1(APOE*2)Mae N9
  • Homozygous for a human APOE2 gene targeted replacement of the endogenous mouse Apoe gene
  • Expresses human apolipoprotein E2 isoform under the control of the murine Apoe regulatory sequences
  • ApoE is a plasma protein involved in cholesterol transport, with three human isoforms (E2, E3, and E4) that have been associated with atherosclerosis and Alzheimer's Disease (AD)
  • E2 is the least common isoform in the human population
  • In humans, the E2 allele decreases the risk and delays onset of AD, but increases the risk of type III hyperlipoproteinemia
  • Develops hyperlipoproteinemia with elevated plasma cholesterol and triglyceride levels, decreased clearance of vLDL particles, and spontaneous atherosclerotic plaques on a normal diet, exacerbated by a high fat diet
  • Useful for studying the role of human APOE polymorphism in atherosclerosis, lipid metabolism and Alzheimer's disease
Orders by weight: Taconic cannot accept orders by weight for this model. Please note that shipments may contain animals with a larger weight variation.

Genetic Background:

Congenic on C57BL/6NTac Background


The APOE2 targeted replacement mouse was developed in the laboratory of Nobuya Maeda at the University of North Carolina. The model was created by targeting the murine Apoe gene for replacement with the human APOE2 allele in E14TG2a ES cells and injecting the targeted cells into blastocysts. Resultant chimeras were backcrossed to C57BL/6 for seven generations (N7). Taconic received stock in 2000. The mice were backcrossed two additional times (N9) and embryo transfer derived. Additional backcrossing to C57BL/6NTac was completed, and the line is now congenic on this B6 substrain. The colony is maintained through incrossing of homozygotes.


Does not carry Nnt mutation





Initial Publication:

Sullivan PM, Mezdour H, Quarfordt SH, Maeda N. (1998) Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse apoe with human APOE*2. J Clin Invest, 102(1):130-5.

Conditions of Use for Taconic Transgenic Models™
Taconic Transgenic Models™ (Models) are produced and distributed under rights to patents and intellectual property licensed from various institutions. Taconic sells the Models to purchasers, grants to each purchaser a right under Taconic's rights in such licensed patents and intellectual property to use the purchased Model in consideration of purchasers' acknowledgement of and agreement to the Terms and Conditions for Taconic Models, Products and Services and the following terms of use:
  • Title to these Models and biological materials derived from them remains with Taconic.
  • The Models will be used for research purposes only.
  • The Models will not be bred or cross-bred except to obtain embryos or fetuses required for research purposes unless additional rights have been granted in writing by Taconic.
  • The Models and biological materials derived from them will not be distributed to third parties or used for commercial purposes.
  • Non-profit purchasers may not use this Model and/or biological materials derived from it in sponsored research or contract research studies unless it is purchased at the for-profit price.

Welcome! Tell us a little about yourself